Endometrial Cancer Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery), By Distribution Channel (Hospitals, Retail Pharmacies, Others), and Region Forecast 2019-2030

Endometrial Cancer Treatment Market size was valued at US$ 27.8 billion in 2023, growing at a CAGR of 6.8% from 2024-2030. Endometrial cancer is the most common female genital cancer that begins in the endometrium of the uterus. Signs and symptoms may include vaginal bleeding and pelvic pain. Usually diagnosed by pelvic examination, ultrasound scanning, and other techniques. Treatment may include, chemotherapy, radiation therapy, or hormonal therapy. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, the global market report includes human demographics; regulatory scenario, and competition analysis with a vividly illustrated competition dashboard to assess the market competition.

Moreover, PBI analyzed the global market to better equip clients with possible investment opportunities across the regions (regional Investment hot spots) and market unmet needs (Product opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in global endometrial cancer treatment products. In September 2019, the US FDA approved Mercks anti-programmed cell death protein 1 (PD-1) Keytruda and Eisais kinase inhibitor Lenvima for certain advanced endometrial carcinoma patients. On May 30, 2019, AbilityPharma (Ability Pharmaceuticals, SL) released the first results of the currently ongoing phase 1/2a clinical trial evaluating ABTL0812 combined with carboplatin and paclitaxel in patients with endometrial cancer or non-small cell lung cancer. The results correspond to the phase 1 part of the Phase 1/2a clinical trial.